Navigation Links
Zimmer and ISTO Technologies Announce Phase III Clinical Study to Evaluate the Effectiveness of Engineered Juvenile Cartilage to Repair Damaged Knees
Date:2/7/2012

SAN FRANCISCO, Feb. 7, 2012 /PRNewswire/ -- Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a global leader in musculoskeletal health, and ISTO Technologies, Inc., an orthobiologics company focused on developing breakthrough products to regenerate and restore function to damaged cartilage and bone, today announced a Phase III clinical study to evaluate DeNovo® ET Engineered Tissue Graft, an engineered cartilage implant intended to repair cartilage defects in the knee.  DeNovo ET Graft is being developed under a collaborative relationship between ISTO and Zimmer. 

"The DeNovo ET Graft program represents a natural extension to our early intervention and joint preservation portfolio," said Cheryl R. Blanchard, Ph.D., Senior Vice President and Chief Scientific Officer at Zimmer.  "This Phase III study will generate meaningful data on the potential of this novel biological solution for treatment of cartilage lesions earlier in the continuum of care."

The Phase III study will comprise a randomized, controlled clinical trial involving 225 patients at up to 25 centers in the United States. The program is designed to demonstrate superiority of DeNovo ET Graft over the current standard of care (microfracture) for articular cartilage defects.  

In preclinical studies, cartilage cells derived from juvenile tissue demonstrated a significantly greater capacity for regenerating cartilage compared to cells derived from adult cartilage.  Recognizing and harnessing the significant regenerative capacity differences between adult and juvenile cells is an underlying principle of ISTO's platform for cartilage repair.  In addition, through a proprietary scalable manufacturing process, ISTO has developed a platform technology for cartilage regeneration using juvenile cartilage cells.

"It is gratifying for our team to see our breakthrough cartilage repair technology advancing from research into a late stage clinical trial for what is clearly a large unmet medical need," said Mitchell Seyedin, Ph.D., President and CEO of ISTO. 

More information about the Phase III clinical study is available at http://www.repairmyknee.com/.

About Zimmer
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products.  Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries.  Zimmer's 2011 sales were approximately $4.5 billion.  The Company is supported by the efforts of more than 8,500 employees worldwide.  For more information about Zimmer, visit www.zimmer.com.

About ISTO

ISTO is a privately-held orthobiologics company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sports medicine applications. ISTO's products are intended for the repair and regeneration of damaged or injured cartilage and bone. For additional information on ISTO, please visit our website at www.istotech.com.  

Zimmer Safe Harbor Statement

This press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 based on current expectations, estimates, forecasts and projections about the orthopaedics industry, management's beliefs and assumptions made by management.  Forward-looking statements may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," and "seeks" or the negative of such terms or other variations on such terms or comparable terminology.  These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that could cause actual outcomes and results to differ materially.  For a list and description of such risks and uncertainties, see our periodic reports filed with the U.S. Securities and Exchange Commission.  We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports.  Readers of this document are cautioned not to place undue reliance on these forward-looking statements, since, while we believe the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate.  This cautionary statement is applicable to all forward-looking statements contained in this document.


'/>"/>
SOURCE Zimmer Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Zimmer Announces Acquisition of Synvasive Technology, Inc.
2. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Fourth Quarter and Year End 2011 Results
3. Zimmer Initiates Quarterly Dividend and Announces New Share Repurchase Program
4. Zimmer Introduces New CLS® Brevius™ Hip Stem with Kinectiv® Technology in the United States
5. Zimmer to Establish Asia-Pacific Research and Development Center
6. Zimmer Announces Acquisition of XtraFix® External Fixation System
7. Zimmer Holdings, Inc. Agrees to Sell $550 Million of Senior Notes
8. Zimmer Holdings, Inc. Announces Offering of Senior Notes
9. Zimmer Introduces inViZia™ Anterior Cervical Plate System at NASS Annual Meeting
10. Zimmer Holdings to Present at 2011 Credit Suisse Annual Health Care Conference
11. Zimmer Holdings, Inc. Reports Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... England och PITTSBURGH ... Erbjudandet lämnas inte, och detta pressmeddelande ... indirekt, i eller till, och inga anmälningssedlar ... av aktieägare i, något land där Erbjudandet, ... accept av Erbjudandet skulle strida mot tillämpliga ...
(Date:2/10/2016)... A new report from business intelligence provider GBI Research ... Alzheimer,s disease market will more than double from just under $5 billion in ... Rate (CAGR) of 11%. Canada , France ... Spain , the UK, and Japan , and ... --> Canada , France , ...
(Date:2/10/2016)... , Feb. 10, 2016 Urologix, the market ... treatment of Benign Prostatic Hyperplasia (BPH), announces new private ... Keswani , a medical device industry veteran of more ... Limited Liability Company.  Plymouth, Minn. ... lines, Cooled ThermoTherapy™ and Prostiva® RF Therapy, will continue ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... Husted Kicking has ... Diego, CA, on February 6th & 7th, 2016 according to kicking coach Michael Husted. ... not invited to the NFL’s combine in Indianapolis,” says Husted. “The NFL uses a ...
(Date:2/11/2016)... AZ (PRWEB) , ... February 11, 2016 , ... As ... with support of the Million Dollar Round Table Foundation (MDRTF), has gifted $10,000 to ... according to Colleen’s Dream Foundation President Billy Cundiff. , “We are honored to support ...
(Date:2/10/2016)... ... February 10, 2016 , ... Early this week, Team Iconic at J. ... Nestlé KITKAT as the first global confectionery brand sourced from 100% sustainable cocoa. , ... quality of their product, through activities that focus on better farming, better lives and ...
(Date:2/10/2016)... Fort Walton Beach, Florida (PRWEB) , ... February ... ... that the innovative weather-forecasting company is unveiling its revolutionary new 2.0 version at ... new platform, MetLoop has “put the power of the world's most advanced weather ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... Guard, to associations of medical professionals throughout the country. The Guard was specifically ... assessments, policies and procedures, employee training, regulatory updates, and compliance coaching. , In ...
Breaking Medicine News(10 mins):